Oakbrook Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Oakbrook Investments’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$313K	Sell	642 -3,249	-84%	-$1.34M	0.8%	48
2019 Q4	$1.46M	Buy	3,891 +1,766	+83%	+$594K	0.3%	61
2019 Q3	$589K	Buy	+2,125	New	+$629K	0.04%	351
2019 Q2	–	Sell	-2,960	Closed	-$1.22M	–	645
2019 Q1	$1.22M	Buy	+2,960	New	+$1.22M	0.07%	215
2018 Q2	–	Sell	-6,465	Closed	-$2.23M	–	601
2018 Q1	$2.23M	Buy	6,465 +3,175	+97%	+$1.1M	0.14%	122
2017 Q4	$1.24M	Sell	3,290 -60	-2%	-$24.3K	0.08%	183
2017 Q3	$1.5M	Buy	3,350 +300	+10%	+$143K	0.1%	166
2017 Q2	$1.5M	Sell	3,050 -3,075	-50%	-$1.35M	0.1%	155
2017 Q1	$2.37M	Buy	+6,125	New	+$2.27M	0.15%	117
2015 Q1	–	Sell	-2,125	Closed	-$872K	–	586
2014 Q4	$872K	Buy	+2,125	New	+$836K	0.05%	301
2014 Q2	–	Sell	-12,487	Closed	-$3.75M	–	635
2014 Q1	$3.75M	Sell	12,487 -2,000	-14%	-$616K	0.12%	192
2013 Q4	$3.99M	Sell	14,487 -588	-4%	-$169K	0.11%	203
2013 Q3	$4.72M	Buy	15,075 +14,125	+1,487%	+$3.72M	0.14%	166
2013 Q2	$214K	Buy	+950	New	+$221K	0.01%	613

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Oakbrook Investments's REGN Position: Q1 2020 in Review

Oakbrook Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 84% in Q1 2020, selling an estimated $1.34M and leaving 642 shares worth $313K. The position accounts for 0.8% of the portfolio, ranked #48.

Oakbrook Investments first reported a position in REGN in Q2 2013 and has held it in 14 quarters since. The position peaked at $4.72M in Q3 2013. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

Oakbrook Investments held 642 shares of Regeneron Pharmaceuticals worth $313K as of Q1 2020.
Oakbrook Investments sold 3,249 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $1.34M.
Regeneron Pharmaceuticals made up 0.8% of Oakbrook Investments's portfolio in Q1 2020, its #48 holding.
Oakbrook Investments first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
Oakbrook Investments's Regeneron Pharmaceuticals position peaked at $4.72M in Q3 2013.
816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Oakbrook Investments's 13F filing for Q1 2020, filed 22 Apr 2020.